Evaluasi Penggunaan Antibiotik Pada Pasien Bronkopneumonia Anak Di Ruang Perawatan Melati Rsud Mukomuko Tahun 2024
DOI:
https://doi.org/10.1144/jscpr.v2i1.433Keywords:
Pediatric Bronchopneumonia, Antibiotics, Treatment, Retrospective, HospitalAbstract
Bronchopneumonia is an inflammatory lung condition affecting one or more lobes, characterized by infiltrative patches caused by bacteria, viruses, fungi, and foreign substances. The purpose of this study was to obtain an overview and analysis of the appropriateness of antibiotic use. This was a descriptive observational study with a retrospective approach using secondary medical record data. The results for the description of antibiotic use were Seftriakson (53.4%), Sefotaksim (27.6%), and meropenem (19.0%). The results of the quality assessment using the Gyssens Method revealed that 1.7% of antibiotic prescriptions were in category III B, 19% in category IV A, and 79.3% in category 0. These data indicate that there is still irrational use of antibiotics. Assessed using the ATC/DDD methodology, resulting in a total of 25.57 DDD per 100 days. The calculation findings show the highest Defined Daily Dose (DDD) value for the antibiotic Seftriakson at 18.06 DDD per 100 days of hospitalization, while the lowest value was seen for Meropenem at 2.09 DDD per 100 days and Sefotaksim at 5.42 DDD per 100 days of hospitalization. Clinical parameters showed a P value > 0.05, with p = 0.88, indicating no statistically significant difference between antibiotic administration and leukocyte levels in pediatric bronchopneumonia patients in the Melati ward at Mukomuko Hospital in 2024.
Downloads
References
Alaydrus, S. (2018). Evaluasi penggunaan antibiotik pada anak penderita bronkopneumonia di Rumah Sakit Provinsi Sulawesi Tengah periode 2017.
Anggara, F., et al. (2014). Pedoman manajemen IDSA untuk pneumonia rawat inap non-ICU.
Astuti, W. T., Marhamah, S., & Diniyah, N. (2019). Bronkopneumonia: karakteristik klinis dan terapi. Jurnal Kesehatan, 9(1), 47–55.
Depkes RI. (2014). Modul Pengendalian Pneumonia Balita. Jakarta: Kementerian Kesehatan RI.
Elvina, R., Rahmi, N., & Oktavira, S. A. (2018). Evaluasi penggunaan antibiotik pada pasien community-acquired pneumonia (CAP) di Instalasi Rawat Inap Rumah Sakit “X” Jakarta. Pharmacy: Jurnal Farmasi Indonesia, 14(1), 64–74.
Gyssens, I. C., et al. (1992). A method for assessing the quality of antimicrobial drug prescribing. Journal of Antimicrobial Chemotherapy, 30(5), 724–727.
Hidayati, N., et al. (2021). Evaluasi penggunaan antibiotik pada pneumonia anak di Indonesia. [Artikel penelitian]. Hopkins, J. (2020). Clinical guidelines for pneumonia management. Baltimore: Johns Hopkins Medicine.
IDAI. (2013). Formularium Spesialistik Ilmu Kesehatan Anak. Ikatan Dokter Anak Indonesia.
Jayesh, M. (2010). Pharmacology of third generation cephalosporins. Journal of Antimicrobial Chemotherapy, 65(4), 45–50. Kementerian Kesehatan Republik Indonesia. (2011). Modul Penggunaan Obat Rasional. Jakarta: Kementerian Kesehatan RI.
Kementerian Kesehatan Republik Indonesia. (2012). Profil Kesehatan Indonesia 2011. Jakarta: Kementerian Kesehatan RI.
Kementerian Kesehatan Republik Indonesia. (2015). Program Pengendalian Resistensi Antimikroba (PPRA). Jakarta: Kementerian Kesehatan RI.
Kementerian Kesehatan Republik Indonesia. (2021). Pedoman Umum Penggunaan Antibiotik. Jakarta: Kementerian Kesehatan RI.
Kementerian Kesehatan Republik Indonesia. (2022). Profil Kesehatan Indonesia 2021. Jakarta: Kementerian Kesehatan RI.
Lisa, A. (2015). Hopkins guidelines for community-acquired pneumonia. Clinical Infectious Diseases, 60(3), 45–49.
Mahbubur Rasyid, et al. (2017). Antibiotic use in pediatric pneumonia patients in Bangladesh. [Artikel penelitian].
Medical Profession Journal of Lampung (MEDULA). (2020). Kasus pneumonia dengan leukosit tinggi. Medula (Medical Profession Journal of Universitas Lampung), 9(4).
Mendao, F., et al. (2020). Rational use of antibiotics in pediatric pneumonia. [Artikel penelitian].
Muhammad, O. R. (2018). Evaluasi penggunaan antibiotik dengan metode ATC/DDD pada pasien pneumonia di Instalasi Rawat Inap RSUD Dr. Moewardi tahun 2017. Skripsi.
Nabila, H. F. (2022). Profil penderita bronkopneumonia pada anak yang dirawat inap di Rumah Sakit Umum Karsa Husada Batu tahun 2020–2021. Universitas Islam Negeri Maulana Malik Ibrahim.
Narita, C., Rahmawati, I., & Virda, E. (2023). Asuhan keperawatan dengan masalah pola napas tidak efektif pada kasus pneumonia di RSU Anwar Medika Sidoarjo. Perpustakaan Universitas Bina Sehat PPNI Mojokerto.
PDPI. (2022). Pedoman Tatalaksana Pneumonia pada Anak. Jakarta: Perhimpunan Dokter Paru Indonesia.
Pratiwi, E. Y., Haryanto, A., & Pratiwi, C. J. (2023). Pengaruh latihan Active Cycle Breathing Technique (ACBT) terhadap perubahan frekuensi napas pada pasien pneumonia. Perpustakaan Universitas Bina Sehat PPNI.
Pratiwi, E. Y., Haryanto, A., & Pratiwi, C. J. (2024). Pengaruh latihan Active Cycle Breathing Technique (ACBT) terhadap perubahan frekuensi napas pada pasien pneumonia. Perpustakaan Universitas Bina Sehat PPNI.
Rahmawati, N. (2019). Efektivitas antibiotik terhadap penurunan suhu dan leukosit pada pasien pneumonia. Jurnal Ilmiah Kesehatan, 11(2), 55–62.
UNICEF/WHO. (2021). Pneumonia: The Forgotten Killer of Children. Geneva: WHO.
Viani, A., Anggi, A., & Sulmba, F. (2019). Pola penggunaan antibiotik pada pasien pneumonia anak. Jurnal Farmasi Klinik Indonesia, 8(2), 110–118.
WHO. (2019). ATC/DDD Index 2019. Geneva: World Health Organization.
WHO. (2022). Haematology Reference Ranges for Children. Geneva: World Health Organization.
WHO. (2023). Child Growth Standards and Age Classifications. Geneva: World Health Organization.
Yanti, R., dkk. (2016). Rasionalitas penggunaan antibiotik pada pasien rawat inap balita penderita pneumonia dengan metode Gyssens di RSUD Sultan Syarif Mohamad Alkadrie Pontianak. Jurnal Mahasiswa Farmasi Fakultas Kedokteran UNTAN, 4.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Elsa Febria Mutiara, Ariesta Kirana Efmisa, Devahimer Harsep Rosi, Aivi Yola Dwiputri

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.





















